--- title: "Afrin (oxymetazoline): 2026 Review" description: OTC alpha-adrenergic decongestant nasal spray. Effective short-term (≤3 days per FDA label); causes rebound congestion with sustained use. canonical: "https://allermi-site.vercel.app/reviews/afrin/" lastReviewed: "2026-05-05T00:00:00.000Z" firstPublished: "2026-05-05T00:00:00.000Z" primaryKeyword: afrin review ymylTier: medium author: name: BestAllergyNasalSprays Editorial Team — Clinical Pharmacy credential: Editorial Pool sameAs: ["https://dailymed.nlm.nih.gov/", "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"] medicalReviewer: name: BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology credential: Editorial Pool sameAs: ["https://www.aaaai.org/", "https://www.acaai.org/"] citations: [] claims: [c-021, c-022, c-046] --- ## TL;DR Afrin (oxymetazoline 0.05%) is an OTC nasal decongestant labeled for short-term use only — no more than 3 days per the FDA label. Sustained use causes rhinitis medicamentosa (rebound congestion). Not an allergy medication. Best for short-term cold congestion or sinus pressure; for daily allergy control, use an intranasal corticosteroid instead. import Claim from '../../components/Claim.astro'; import CitationList from '../../components/CitationList.astro'; Rhinitis medicamentosa is caused by prolonged use of topical nasal decongestant sprays — primarily the alpha-adrenergic vasoconstrictors such as oxymetazoline (Afrin), xylometazoline, naphazoline, and phenylephrine. The FDA label for OTC decongestant sprays advises against use beyond 3 days; case-series literature most often describes onset after about 5–7 days of continuous use, with onset varying widely. The FDA label for Afrin Original (oxymetazoline hydrochloride 0.05% nasal spray) instructs consumers to not use the product for more than 3 days, warning that frequent or prolonged use may cause nasal congestion to recur or worsen. In a small randomized crossover trial (Vaidyanathan 2010, n=19 healthy adults), adding intranasal fluticasone after 14 days of oxymetazoline reversed the tachyphylaxis and rebound congestion induced by the decongestant. ## Best fit Afrin (oxymetazoline 0.05%) is an over-the-counter alpha-adrenergic vasoconstrictor decongestant. Best for **short-term** congestion relief (3 days max per FDA label) — colds, post-flight congestion, acute sinus pressure. Not a long-term allergy treatment. ## Why we don't recommend daily Sustained Afrin use causes rhinitis medicamentosa (rebound congestion). Recovery requires stopping Afrin and starting an intranasal corticosteroid; expect symptom improvement within 48 hours and full mucosal recovery in 1–2 weeks (see [our rebound recovery guide](/guides/rebound-recovery/)). ## How Allermi handles oxymetazoline differently Allermi formulations include oxymetazoline at 0.003125–0.0125% — roughly 1/4 to 1/16 the 0.05% concentration in OTC Afrin — paired with an intranasal corticosteroid. In short-term randomized trials of corticosteroid + oxymetazoline co-administration (Baroody 2011 PMID 21377716, Kumar 2022 PMID 35712651), no rhinitis medicamentosa signal has been detected at 4–28 days; long-term safety beyond a few weeks has not been established. See the [Allermi review](/reviews/allermi/) for full formulation specs.